Michael Agius, PhD

Dana-Farber Cancer Institute
Department of Medical Oncology
Boston, MA
USA Papers:
154 Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
4681 A Rationally Designed Novel Polymer for Safe and Synergistic Delivery of High Dose Bortezomib, Pomalidomide/Lenalidomide, and Dexamethasone for Multiple Myeloma